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Abstract
Background: Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs)
was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progression-
free survival (PFS) versus placebo.
Methods: During CLARINET, patients with metastatic intestinal/pancreatic NETs received lanreotide depot/autogel
120 mg or placebo every 4 weeks for 96 weeks. Imaging data (response evaluation criteria in solid tumors [RECIST]
v1.0, centrally reviewed) were re-evaluated in this post hoc analysis of tumor growth rate (TGR) in NETs. TGR
(%/month) was calculated from two imaging scans during relevant periods: pre-treatment (TGR0); 12–24 weeks
before randomization versus baseline; each treatment visit versus baseline (TGRTx-0); between consecutive treatment
visits (TGRTx-Tx). To assess TGR as a measure of prognosis, PFS was compared for TGR0 subgroups stratified by
optimum TGR0 cut-off; a multivariate analysis was conducted to identify prognostic factors for PFS.
Results: TGR0 revealed tumors growing during pre-treatment (median [interquartile range] TGR0: lanreotide 2.1%/
month [0.2; 6.1]; placebo 2.7%/month [0.15; 6.8]), contrary to RECIST status. TGR was significantly reduced by 12
weeks with lanreotide versus placebo (difference in least-square mean TGR0–12 of − 2.9 [− 5.1, − 0.8], p = 0.008), a
difference that was maintained at most subsequent visits. TGR0 > 4%/month had greater risk of progression/death
than ≤4%/month (hazard ratio 4.1; [95% CI 2.5–6.5]; p < 0.001); multivariate analysis revealed lanreotide treatment,
progression at baseline, TGR0, hepatic tumor load, and primary tumor type were independently associated with PFS.
Conclusions: TGR provides valuable information on tumor activity and prognosis in patients with metastatic
intestinal/pancreatic NETs, and identifies early lanreotide depot/autogel antitumor activity.
Trial registration: Retrospective registration, 18 July 2006; EudraCT: 2005–004904-35; ClinicalTrials.gov: NCT00353496.
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Background
Neuroendocrine tumors (NETs) are slow-growing neo-
plasms that arise from diverse locations, including the pan-
creas and gastrointestinal (GI) tract. The prognosis of NETs
is heterogeneous and tumor progression has been utilized
in most phase-3 clinical trials to refine prognostic stratifica-
tion. Current knowledge of well-differentiated NET growth
kinetics and the relationship to treatment are limited; fur-
ther understanding may improve the assessment of NET
progression, prognosis and ultimately treatment.
Response evaluation criteria in solid tumors (RECIST) is
used by oncologists and radiologists, and recognized by
regulatory bodies as an assessment of tumor response to
therapy, including NETs [1, 2]. RECIST estimates change
in tumor burden using the sum of the longest diameters
(SLD) of target lesions over a course of treatment which,
together with the appearance of new lesions, is trans-
formed into a categorical variable (complete response
[CR], partial response [PR], stable disease [SD], or pro-
gressive disease [PD]) [1, 2].
Although a valuable tool widely used in clinical trials,
RECIST is a qualitative variable, overemphasizing tumor
shrinkage as a successful response to treatment, and re-
quires improved reproducibility [3, 4]. Limitations of
RECIST extend to accurate assessment of NET disease
status, which can be confounded by their slow growth
kinetics [5]. As a result, it can be difficult for practi-
tioners to decide how to adapt treatment. Therefore, a
metric that provides a more sensitive measure of tumor
growth would prove advantageous in slow-growing
tumor assessment, including NETs.
An assessment providing dynamic and quantitative
evaluation of tumor kinetics may offer a useful comple-
ment to RECIST. Tumor slope has been explored as a
prognostic factor in studies on solid tumors [6–10], in-
cluding well-differentiated NETs [9, 10]. Tumor growth
rate (TGR), which is based on change in tumor volume,
has been independently associated with progression-free
survival (PFS) using data from phase-1 studies in solid
tumors (including upper GI and pancreatic tumors) [11],
and with PFS and overall survival (OS) using data from
the phase-3 TARGET study (sorafenib compared with
placebo) in metastatic renal cell carcinoma (mRCC) [12].
More recently, an association of TGR with PFS has been
reported in a post hoc analysis from a phase-2
single-arm trial of lanreotide depot/autogel 120 mg for
non-functioning intestinal/pancreatic NETs in Japanese
patients [13].
The CLARINET core study demonstrated the antitu-
mor efficacy of lanreotide depot/autogel 120mg/4 weeks
in patients with non-functioning intestinal/pancreatic
NETs compared with placebo [14]. The CLARINET
open-label extension confirmed long-term safety and ef-
ficacy [15]. Most participants in the core study had SD
at baseline according to RECIST v1.0. In these post hoc
analyses, core study tumor growth measurements were
evaluated using TGR as a measure of tumor progression
and response before and during treatment, and as a
prognostic factor for PFS.
Methods
Patients and study design
The design and methods for the CLARINET study have
been described previously [14]. In brief, patients had unre-
sectable, locally advanced or metastatic, well/moderately
differentiated, somatostatin receptor-positive NETs with
Ki-67 up to 10%. NETs were non-functioning except for
gastrinomas controlled by proton-pump inhibitors for ≥4
months. Tumors originated in the pancreas, midgut or
hindgut, or were of unknown origin.
The CLARINET study was an international, randomized,
double-blind, placebo-controlled phase-3 trial (EudraCT:
2005–004904-35; ClinicalTrials.gov: NCT00353496). Pa-
tients received lanreotide 120mg (n = 101) or placebo (n
= 103) once every 4 weeks, for 96 weeks or until PD
(assessed centrally using RECIST v1.0) or death. The study
was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practice Guidelines, and local regu-
latory requirements. Trial documentation was approved by
institutional review boards at each study site, and all
patients provided written informed consent. A full list of
the ethics committees and their institutions is provided
Appendix 1 of in the Additional file 1.
Assessments and endpoints
Study visits were scheduled during the screening period
and at weeks 1 (baseline), 12, 24, 36, 48, 72, and 96 [14].
Baseline disease-progression status according to RECIST
v1.0 was determined over a 12- to 24-week screening
period [14]. Computed tomography or magnetic reson-
ance imaging of the chest, abdomen and pelvis was per-
formed twice during screening. Changes in target-lesion
sizes were assessed from the second imaging test
(performed 12–24 weeks after the first scan), and
randomization took place within the following 4 weeks.
Single scans were obtained at post-baseline visits and
reviewed centrally according to RECIST v1.0. If a patient
was withdrawn from the study prematurely for reasons
other than PD/death, further imaging was undertaken
(unless already undertaken within the previous 4 weeks).
TGR was expressed as the percentage change in tumor
volume over 1month (%/month): TGR = 100 × (exp(TG)–
1), where TG= 3 × log(D2/D1)/time (months) [11, 12].
Tumor size (D) was determined using the SLD of target
lesions only (according to RECIST v1.0); non-target and
new lesions were not considered. D1 and D2 represent
tumor sizes at evaluation dates 1 and 2; and time
(months) = (date 2 – date 1 + 1)/30.44.
Dromain et al. BMC Cancer           (2019) 19:66 Page 2 of 9
The clinical utility of TGR was assessed: by evaluating
pre-treatment TGR (TGR0) using the two scans per-
formed during screening; by calculating the change in
TGR between pre-treatment and a visit during treatment
(TGRTx–0); and by calculating the TGR between consecu-
tive visits during treatment (TGRTx–Tx). To investigate the
value of TGR0 as a prognostic factor for tumor progres-
sion (according to RECIST v1.0), the optimum TGR0
cut-off value (%/month) was determined, and PFS was
compared for TGR0 subgroups stratified by the optimum
TGR0 cut-off. Exploratory analyses were also conducted to
identify potential prognostic factors for PFS (according to
RECIST v1.0). Analyses were carried out to determine
whether Ki-67 correlated with TGR0 in all patients with a
tumor biopsy; and in a subgroup of patients with a tumor
biopsy taken within 1 year of starting treatment.
Statistical methods
A priori summary statistics were prepared for baseline
characteristics based on the intention-to-treat (ITT) popu-
lation (all randomized patients) [14]. All other analyses
were post hoc and based on the ITT population, or a spe-
cified subset thereof. Spearman’s rank correlation was
used to test for an association between Ki-67 at screening
and TGR0. TGRs during the study were analyzed using
mixed-model regression analyses with repeated measures;
least square (LS) means and 95% confidence intervals
(CIs) were calculated by visit for each treatment.
To explore TGR as a prognostic factor, a receiver oper-
ating characteristic (ROC) analysis was conducted to de-
termine the optimum TGR0 cut-off value associated with
risk of PD (according to RECIST v1.0) or death. PFS was
estimated using the Kaplan–Meier method and compared
between lanreotide and placebo according to subgroups
defined by the TGR0 cut-off value using the log-rank test.
Comparisons were also made between the TGR0 sub-
groups within each treatment group. In an additional ana-
lysis, PFS was estimated between lanreotide and placebo
for the subgroups TGR0 > 4%/month and ≤ 10%/month;
and TGR0 > 10%/month. To explore the prognostic value
of absolute TGR at 12 weeks (TGR0–12), an association be-
tween TGR0–12 and PFS was assessed for lanreotide and
placebo groups. Hazard ratios (HRs) were estimated from
Cox proportional hazard models. Patients with PD due to
non-target or new lesions were excluded from these
subgroup analyses. The prognostic value of TGR0 was fur-
ther explored using a Cox proportional hazards model to
identify potentially important covariates (Wald Chi-square
p < 0.10, Additional file 1: Table S1). These covariates
were analyzed via a multivariate Cox proportional hazard
model of PFS; only covariates potentially important in the
presence of other terms (p < 0.10) remained in the final
model. All statistical analyses were carried out using SAS
statistical software (SAS V9.4).
Results
Patients
The patient population has been described previously
[14]. Briefly, 204 patients were randomized (ITT popula-
tion) to receive lanreotide (n = 101) or placebo (n
= 103). Most patients had received no previous treat-
ment (84%, 172/204) and had SD over the 12- to
24-week screening period before study entry (96%, 195/
204), according to RECIST v1.0 [14]. Mean (standard de-
viation) time between diagnosis and enrollment was 33.5
(43.7) months. All patients had grade 1 or low-grade 2
tumors (Ki-67 < 10%). Overall, 33% (67/204) of patients
had hepatic tumor loads over 25%; 45% (91/204) had
primary tumors of the pancreas and 36% (73/204) of the
midgut. In total, 200 patients with evaluable data and
available SLD measurements were included in these post
hoc analyses. Patients were excluded if they had: missing
SLD; a change in TGR that could not be measured; or
non-target or new lesions (Additional file 1: Figure S1).
Use of TGR to measure tumor progression and response
before and during treatment
The distributions of patient TGR0 during the pre-treatment
period were similar for both treatment groups (post hoc
analyses; ITT population; Fig. 1a). Overall, patients receiv-
ing lanreotide had a median (interquartile range) TGR0 of
2.1%/month (0.2–6.1), while those receiving placebo had
2.7%/month (0.15–6.8). The majority of patients, including
those with SD, had increases in SLD measurements during
the pre-treatment period (Fig. 1b). We observed no correl-
ation between Ki-67 at screening and TGR0 in analyses that
included either all patients with a tumor biopsy, or a sub-
group of patients with a tumor biopsy taken within 1 year
of starting treatment (Additional file 1: Figure S2).
When using TGR to measure proliferative activity during
treatment, variation between TGR0 and each study visit
(TGRTx–0) according to RECIST v1.0 status revealed that a
large proportion of patients had reductions in TGR at
post-treatment visits relative to TGR0 (Additional file 1:
Figure S3), with greater reductions in lanreotide compared
with the placebo group. These findings were despite most
patients being classified as SD with RECIST v1.0, regardless
of treatment. A disparity between median TGR0 and LS
mean TGR0 in the lanreotide group was due to high TGR0
in two patients. Calculation of TGRs between consecutive
visits during treatment (TGRTx–Tx) revealed a reduction in
TGR as early as week 12 of lanreotide treatment (TGR0–12),
resulting in a statistically significant difference between
treatment groups that was maintained throughout most of
the treatment period (Fig. 2; Additional file 1: Table S2). In-
dividual TGRs (TGRTx–Tx) for patients with PD after the
start of treatment revealed that, in many cases, PD was a
result of accumulated tumor growth over time, rather than
a sudden increase in TGR (Additional file 1: Figure S4).
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Fig. 1 Distribution of (a) TGR0 and (b) percentage change in SLD among patients during the pre-treatment period. a Distribution of TGR0 among
patients during the pre-treatment period according to RECIST v1.0 classification. Individual data points represent the TGR0 in individual patients
(ITT population), according to their classification by RECIST v1.0. Boxes represent median and interquartile range (Q1–Q3), whiskers represent the
minimum observation still within 1.5 IQR of lower quartile (Q1), and the maximum observation still within 1.5 IQR of the upper quartile (Q3).
Median (IQR) TGR0: 2.1%/month (0.2; 6.1) (lanreotide 120 mg); 2.7%/month (0.15; 6.8) (placebo). b Percentage changes in SLD during the pre-
treatment period among individual patients (ITT population). Data are sorted from high percentage change in SLD to low percentage change in
SLD over the pre-treatment period. A patient with a change in SLD less than 20% had PD due to the presence of new lesions. Lanreotide 120
mg, n = 100; placebo, n = 100. ITT, intention-to-treat; IQR; interquartile range; PD, progressive disease; RECIST, response evaluation criteria in solid
tumors; SLD, sum of longest diameters; TGR0, pre-treatment tumor growth rate
Fig. 2 Estimated TGR0 and TGRTx–Tx. *Pre-treatment TGR (TGR0) is calculated from the second imaging test during the screening period
(performed 12–24 weeks after the first screening period scan). LS means and P-values are derived from a mixed model with repeated measures.
CI, confidence interval; LS, least squares; TGR, tumor growth rate; TGR0, pre-treatment TGR, TGRTx–Tx, TGR between consecutive study visits
during treatment
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Use of TGR0 as a prognostic factor
Of the TGR0 thresholds assessed by ROC analysis, a cut-off
TGR0 of 4%/month during the pre-treatment period had
optimal association with the risk of PD (according to
RECIST v1.0 status) or death independently of treatment
group (Additional file 1: Figure S5). When comparing PFS
between TGR0 subgroups, TGR0 > 4%/month was associ-
ated with a four-fold greater risk of PD/death than TGR0 ≤
4%/month in the overall population (HR 4.1 [95% CI [2.5–
6.5]; p < 0.001, n = 187), and within each treatment group
(Additional file 1: Figure S6). When considering PFS within
TGR0 subgroups between treatment groups, lanreotide was
significantly more effective than placebo at reducing the
risk of PD/death, by 73 and 63% in those with TGR0 ≤ 4%/
month and > 4%/month, respectively (Fig. 3). In a separate
analysis, lanreotide reduced the risk of PD/death by 73%
compared with placebo in a subgroup of patients with
TGR0 > 4%/month and ≤ 10%/month (Additional file 1:
Figure S7). There was a trend towards increased PFS with
lanreotide compared with placebo in patients with TGR0 >
10%/month, however this did not reach statistical signifi-
cance. Thirteen patients considered to show disease pro-
gression based only on non-target or new lesions were
excluded from these analyses (lanreotide, n = 6; pla-
cebo, n = 7). The prognostic value of early
on-treatment TGR (TGR0–12) was also explored. Ana-
lyses within each treatment group indicated that a
higher TGR0–12 was associated with worse PFS in both
lanreotide (HR for a 10%/month increase in TGR0–12:
8.0 [95% CI [3.0; 21.3], p < 0.0001, N = 90) and placebo
groups (HR for a 10%/month increase in TGR0–12: 8.8
[95% CI [4.4; 17.6], p < 0.0001, N = 93).
An exploratory analysis of 15 potential prognostic fac-
tors for PFS identified seven potentially important covar-
iates (p < 0.10; Additional file 1: Table S1). A separate
analysis, restricted to the subgroup of patients with
tumor biopsies taken within 1 year of treatment start,
confirmed that neither Ki-67 (p = 0.5917; N = 126) nor
tumor grade (p = 0.5294; N = 125) were potentially im-
portant prognostic factors for PFS in this subgroup of
patients. When the seven potentially important covari-
ates were included into a multivariate model, chromo-
granin A (CgA) levels at baseline, body mass index
(BMI), sex and tumor grade were no longer significant
at p = 0.10 in the presence of the other terms and were,
therefore, excluded from the final multivariate model.
The final model showed TGR0 > 4%, hepatic tumor load
(> 25%–≤50 and > 50%), progression at baseline, and a
pancreatic primary tumor were independent prognostic
factors for worse PFS (according to RECIST v1.0), while
prior therapy was not prognostic for PFS in the presence
of other terms (Fig. 4). After adjustment for these prog-
nostic factors, lanreotide reduced the risk of progression
or death by 69% versus placebo. Risk of PD/death was
more than three-fold higher in patients with TGR0 > 4%/
month.
Discussion
These post hoc analyses were conducted to evaluate the
clinical utility of TGR as a measure of tumor progres-
sion, response and prognosis in patients with intestinal/
pancreatic NETs receiving lanreotide or placebo, using
data from the CLARINET study [14]. Analyses of the
use of TGR to assess tumor progression before treat-
ment (TGR0) revealed a large proportion of patients’ tu-
mors were actively growing during the pre-treatment
period, despite classification as SD according to RECIST
v1.0. There was no correlation between Ki-67 at screen-
ing and TGR0, despite an attempt to stratify the data by
only including patients with biopsies taken within 1 year
of treatment start. Analyses of the use of TGR to assess
proliferative activity during treatment (TGRTx–0) showed
a large proportion of patients had reductions in TGRTx–
0, which tended to be greater with lanreotide compared
Fig. 3 PFS in patients with (a) TGR0 ≤ 4%/month and (b) TGR0 > 4%/month. Analysis of PFS considers centrally assessed disease progressions
(using RECIST v1.0 criteria) and any deaths reported during the study as events. A total of 14 patients in progression purely due to non-target or
new lesions were excluded. TGR0 ≤ 4%, lanreotide n = 56; placebo n = 53; TGR0 > 4%, lanreotide n = 38; placebo n = 40. HRs are derived from a
Cox proportional hazards model. P-values are derived from the log-rank test. CI, confidence interval; HR, hazard ratio; PFS, progression-free
survival; TGR, tumor growth rate; TGR0, pre-treatment TGR
Dromain et al. BMC Cancer           (2019) 19:66 Page 5 of 9
with placebo, while most patients were still classified as
SD according to RECIST v1.0. TGRTx–Tx demonstrated
the antitumor efficacy of lanreotide compared with pla-
cebo, as early as 12 weeks into treatment, by reduction
and subsequent stabilization. Analyses of the use of
TGR0 as a prognostic factor showed that by using a
TGR0 cut-off of 4%/month (found to have optimal asso-
ciation with risk of PD/death by ROC analysis), patients
with TGR0 > 4%/month had a four-fold higher risk of
PD/death compared with ≤4%/month, in the overall
population and within both treatment groups. TGR0–12
was also found to be prognostic for PFS in both treat-
ment groups. A multivariate analysis identified five fac-
tors independently associated with PFS: lanreotide
treatment, progression at baseline, TGR0, hepatic tumor
load (> 25%–≤50 and > 50%), and primary tumor type.
Ki-67 at baseline was not identified as a potentially im-
portant prognostic factor for PFS, prior therapy (yes)
was not prognostic in the presence of other terms and,
notably, CgA at baseline, and tumor grade were ex-
cluded from the final model.
The findings from the present analyses accord with
other similar analyses. The advantage of TGR as a rapid
measure of tumor response has been reported previously;
TGR identified antitumor efficacy during treatment at the
first tumor evaluation in phase-1 and -3 studies of mRCC
[11, 12, 16]. The utility of TGR in non-functioning intes-
tinal/pancreatic NETs was first described in a recent
single-arm phase-2 trial of 32 Japanese patients [13]. A
numerical reduction in TGR was identified within 12
weeks of initiating lanreotide treatment, despite 65% of
patients being classified as PD at baseline (RECIST v1.1),
and was sustained from pre-treatment to last-value [13].
Our analyses expand upon this study in four ways: firstly,
they reveal that TGR can detect early differences between
lanreotide and placebo groups, despite the slow growth
kinetics of NETs; secondly, they demonstrate sustained
lanreotide antitumor activity compared with placebo using
the large dataset from CLARINET; thirdly they provide
additional evidence that although lanreotide reduced TGR
versus placebo overall, tumor growth was ongoing in
many patients, including those classified as having SD;
and finally, in many cases a PD event was the result of on-
going tumor growth, rather than the result of a sudden in-
crease in TGR. Our findings regarding the utility of TGR
during treatment (TGRTx) for monitoring tumor response
and the durability of drug effect also resonate with other
analyses from phase-2 and -3 trials in other tumor types
[6, 12, 17, 18]. TGR0 measurements were suggestive of ac-
tively growing tumors and, as seen with other tumor
types, TGR0 did not reflect RECIST status during
pre-treatment and early treatment evaluation [11, 12, 19].
Others have highlighted the inadequacies of RECIST as a
measure of tumor response because it involves condensing
information into four categories that are defined before
treatment, regardless of growth kinetics. Additionally,
RECIST may not always be relevant for slow-growing tu-
mors or treatments that stabilize growth, and any ob-
served pseudoprogression, even if uncommon in NETs,
may be misrepresented as PD by RECIST [3, 19, 20]. Our
findings that a TGR0 cut-off of 4%/month and TGR0–12
are prognostic for PFS are consistent with others who
identified an association between growth kinetics and clin-
ical outcomes. In a large retrospective analysis of 20
phase-1 mRCC trials, a 9% decrease in progression hazard
was observed with every 10% decrease in TGR (reference
compared with experimental period) [11], and TGR was
associated with PFS regardless of treatment (sorafenib or
Fig. 4 Potential prognostic factors for PFS (final multivariate model). *According to RECIST v1.0. Hazard ratios [95% CI] for centrally assessed PD or
death were generated from a post hoc multivariate Cox proportional hazards model. Four patients with missing TGR0 were excluded from the
model. There were limited patients with progression at baseline (n = 8) and primary tumor type: hindgut n = 14. CI, confidence interval; PD,
progressive disease; PFS, progression-free survival; RECIST, response evaluation criteria in solid tumors; TGR0, pre-treatment tumor growth rate
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placebo) in a retrospective analysis from the phase-3 TAR-
GET trial in mRCC [12]. A new response metric for glio-
blastoma incorporating a linear model of radial tumor
expansion computed at first post-radiation scan was prog-
nostic for PFS, and agreed with more complex anatomic
and spherical equivalents [21, 22]. In addition, response
outcomes utilizing growth dynamics have also been previ-
ously shown to be prognostic for OS in renal and prostate
cancer [12, 17, 18, 21–23]. The TGR0 cut-off of 4%/month
could, therefore, be of value within routine clinical prac-
tice by providing a prognosis for PFS before treatment
start, thus allowing clinicians to make earlier decisions re-
garding future treatment. TGRTx-0 would also be poten-
tially useful in the clinic to identify patients who are or are
not benefitting early in the course of their treatment (e.g.
TGR12–0). TGR0 (≤/> 4%/month), if confirmed to be prog-
nostic for other therapies, and TGRTx-0 would be of par-
ticular importance when planning and monitoring more
toxic treatments, such as peptide receptor radionuclide
therapy and chemotherapy, ensuring these are continued
only for as long as is necessary.
The lack of correlation between Ki-67 and TGR0 in
this analysis was surprising. However, known difficulties
in assessment of the Ki-67 index (intra- and intertu-
moral staining heterogeneity and counting methods, for
example) may, in part, account for this [24, 25]. Ki-67
was not identified as a potentially important prognostic
factor for PFS from the exploratory multivariate analysis,
despite the known importance of Ki-67 as a prognostic
marker in NETs [26]. Nevertheless, our findings accord
with a previous exploratory analysis of prognostic factors
using data from the CLARINET study [27]. Despite be-
ing of potential interest in the univariate setting, CgA
levels at baseline, tumor grade, BMI, and sex were ex-
cluded from the final multivariate model presented here.
Reassuringly, this resonates with previous analyses of
prognostic factors for PFS [13, 27], suggesting CgA
levels and tumor grade are less robust prognostic factors
than hepatic tumor load and TGR0 in patients with
NETs.
This study was not without limitations. There are in-
herent limitations in post hoc analyses that potentially
limit their interpretation. Any confounding due to an-
isotropy was not accounted for, as target lesions were as-
sumed to be spherical, although this does tend to be the
case for liver metastases. Target lesions followed for
TGR may be slow growing, and all lesions within a pa-
tient were assumed to be similar; therefore, TGR for an
individual may not be representative of their overall
tumor targets. Inaccuracies in TGR may be introduced
by errors in SLD measurements and, as tumor growth
was assumed to be exponential, deviations from this
growth pattern; in addition, for TGRTx-0, lesions used for
the tumor assessments during the screening period did
not have to be the same lesions as those assessed during
the treatment period. In concordance with the SLD cal-
culation used in RECIST v1.0, non-target and new le-
sions were not considered in TGR calculations. The
Ki-67 and TGR0 correlation analysis and exploratory
analysis of the prognostic value of Ki-67 were limited
due to a number of reasons. Firstly, many tumor biop-
sies were collected several years before the start of treat-
ment, although additional analyses (restricted to the
subgroup in whom biopsies were taken in the year be-
fore treatment initiation) provided similar results to the
overall population. Secondly, Ki-67 data were either un-
reliably quantified or missing for 41 patients who were
enrolled into the CLARINET study based on mitotic
index. Thirdly, a number of patients had Ki-67 values re-
corded as < 1% (N = 15) or < 2% (N = 29), which re-
stricted the way Ki-67 data could be handled; and few
patients (N = 17) with Ki-67 values > 5% were included.
The ROC area-under-curve implied that TGR0 4%/
month cut-off was not strongly deterministic of PFS.
Further validation will be required to determine whether
this cut-off is relevant in other study populations. Thir-
teen patients with progression based on non-target or
new lesions were excluded from the prognostic value
analysis of the TGR0 4%/month cut-off. However, as a
similar number of patients were excluded in each treat-
ment group, it is unlikely to have affected the results.
These limitations notwithstanding, our findings suggest
TGR has potential clinical utility as a novel metric for pro-
liferative activity, particularly in future studies of somato-
statin analogs or novel targeted therapies in NETs in which
subtle changes in tumor growth are expected but may not
be identified using RECIST. Further advantages of TGR
utility include its potential in individualizing patient treat-
ment, with the possibility that therapy can be adjusted
based on a more precise analysis of tumor kinetics.
Conclusion
Overall, these post hoc analyses of TGR to assess activity be-
fore and during treatment revealed that TGR0 and TGRTx
provided valuable information on tumor kinetics. Evaluation
of TGR0 as a prognostic factor revealed TGR0 was prognos-
tic for PFS, irrespective of treatment. Furthermore, lanreo-
tide was more effective than placebo in delaying PD/death,
irrespective of the TGR0 4%/month cut-off. Future perspec-
tives include the development of TGR-based categorical def-
initions of disease status, and further validation of TGR as a
predefined endpoint in prospective studies.
Additional file
Additional file 1: Table S1. Categories tested in the exploratory
multivariate analyses of potential prognostic factors. Table S2. TGR0 and
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TGRTx–Tx for patients receiving lanreotide or placebo (%/month). Figure S1.
Patient disposition in the CLARINET TGR analysis. Figure S2. Correlation
between TGR0 and Ki-67 at screening in (a) all patients and (b) in a subgroup
of patients with a tumor biopsy taken within 1 year of the start of treatment
(ITT population). Figure S3. Variation in TGR and tumor response evaluation
by RECIST v1.0 between pre-treatment and each treatment visit (TGRTx-0) at
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